The Arizona stem cell bill known as SB 1214 passed both chambers of the Legislature in 2026 and then stopped. Governor Katie Hobbs vetoed it on June 19, 2026, and no override followed. Arizona has no stem cell disclosure or consent statute today. This article covers what the bill would have required and what applies instead.
TLDR: Arizona SB 1214, whose own short title was the Arizona Stem Cell and Regenerative Therapy Act, was vetoed by Governor Katie Hobbs on June 19, 2026. It never became law, so none of its requirements bind anyone. Had it taken effect, it would have required provider continuing education, an all-caps advertising disclosure, a five element written consent, accredited sourcing, and adverse event reporting within 15 calendar days. Arizona providers follow federal rules instead. Banking adipose tissue is a preservation service, and it does not guarantee eligibility, access, or future clinical benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures, and nothing here interprets Arizona law for any practice or patient. Adipose tissue banking is a preservation service, and Save My Fat does not guarantee eligibility, access, or clinical benefit from any future pathway. The summaries below are provided for educational purposes only and are not legal advice. Patients and providers should consult their own licensed healthcare professionals, and providers should consult qualified counsel, before acting on anything described here.
State legislatures moved fast on regenerative medicine in 2026. Georgia enacted Act 453 and Tennessee enacted Public Chapter 1016, both effective July 1, 2026. Wyoming signed its Stem Cell Freedom Act on March 6, 2026, and Utah amended its statute effective May 6, 2026. Arizona looked like the next state in line.
SB 1214 cleared the Arizona Senate on March 4, 2026, passed the House on June 9, 2026, and returned for final Senate passage on June 12, 2026. One week later the governor vetoed it, and there was no override vote. That matters because industry summaries still list Arizona beside states with live disclosure requirements. Knowing the difference between a proposed stem cell law and an enacted one keeps providers from building compliance programs around text with no legal force.
What Happened to the Arizona Stem Cell Bill
SB 1214 was introduced in the Fifty-seventh Legislature, Second Regular Session. The Senate passed it on March 4, 2026 by 18 to 12. The House passed it on June 9, 2026 by 38 to 18, with four members not voting. The Senate gave final passage on June 12, 2026 by 16 to 13. The official bill text remains public.
Had it become law, the measure would have added two sections to the Arizona Revised Statutes, A.R.S. 32-3235 and 32-3236. Inside the bill, the short title was the Arizona Stem Cell and Regenerative Therapy Act, slightly longer than the shorthand many write-ups use. Because the veto stood, neither section exists.
What SB 1214 Would Have Required
Provider education and patient disclosure
The bill would have required nationally recognized accredited or board-recognized continuing education for the provider. It would have added an all-caps advertising disclosure and a written informed consent with five elements. Those covered serious risks, anticipated benefits, alternatives including no treatment at all, and encouragement to consult a primary care provider. Florida, Georgia, Tennessee, and Utah build their statutes on the same two pillars.
Sourcing and product documentation
Products would have come from an FDA-registered facility, or one accredited by the World Marrow Donor Association, the Association for the Advancement of Blood and Biotherapies, the American Association of Tissue Banks, or the American Academy of Stem Cell Medicine. Manufacturers would have supplied viability and surface marker reports, Wharton’s jelly viscosity, exosome particle counts, and lot sterility reports. Supply contracts would have disclosed where and when cells were obtained.
Reporting and a private right of action
Serious adverse events would have gone to the regulatory board within 15 calendar days. The bill also carried a private right of action, with 10,000 dollars in statutory damages per violation plus attorney fees. No enacted law in this group pairs disclosure duties with private enforcement. Scope reached materials from adult donors or from afterbirth, so adipose tissue sat inside the definition.
How Arizona Compares With States That Passed Laws
Setting the vetoed Arizona text beside enacted statutes shows how far apart these frameworks sit. Several states now require a patient facing notice and a written consent, one adds a duty on suppliers, and one covers autologous cells only. The table below shows where each stands.
| State | Status as of July 2026 | Patient facing notice | Written consent |
|---|---|---|---|
| Arizona SB 1214 | Vetoed June 19, 2026, not law | Would have been all-caps | Would have had five elements |
| Florida | Law since July 1, 2025 | Required, exact wording | Required |
| Georgia | Law since July 1, 2026 | Required, exact wording | Required and signed |
| Tennessee | Law since July 1, 2026 | Required, exact wording | Required before the therapy |
| Utah | Amended effective May 6, 2026 | Required, forty point type | Required |
| Wyoming | Law since July 1, 2026 | None in the act | Required |
| Nevada | 2009 statute, permissive | Not required by statute | No stem cell specific rule |
Arizona is the only row describing something that never took effect. Florida also limits non-FDA-approved stem cell therapy to orthopedics, wound care, or pain management, and Tennessee alone sets numeric viability thresholds. Providers tracking the national pattern will recognize the split from our state law map.
What the Veto Means for Arizona Providers Today
With no state statute, the federal framework is the operative rulebook. Human cells, tissues, and cellular and tissue based products fall under 21 CFR Part 1271, which sets registration, donor eligibility, and current good tissue practice obligations. That framework applied in Arizona before SB 1214 was introduced, and it applies unchanged now.
The threshold question sits in 1271.10(a). A product stays solely under Part 1271 only when it meets all four criteria: minimal manipulation, homologous use only as reflected by labeling and advertising, no combination with another article except water, crystalloids, or a preserving agent raising no new safety concerns, and no systemic effect or metabolic dependence unless the use is autologous.
Advertising is the second exposure. The FTC applies its Health Products Compliance Guidance from December 2022, which requires competent and reliable scientific evidence behind health claims and clear and conspicuous disclosures. The FDA also publishes a consumer alert listing conditions these products are not approved to address. Enforcement is real here: the FDA issued a warning letter to Innate Healthcare Institute in Scottsdale on August 15, 2025. The veto changed the state picture, not the federal one.
What This Means for Adipose Tissue Banking in Arizona
Save My Fat connects patients and providers with a United States tissue bank. It does not collect, process, store, or treat. Adipose tissue and stromal vascular fraction remain investigational, and no FDA-approved product exists for either. Banking preserves tissue for potential future participation in FDA-regulated pathways.
After the veto, the practical answer for providers is documentation discipline. Sourcing records, chain of custody, sterility and viability documentation, and accurate advertising carry weight under federal rules with or without a state mandate. Utah went the other way in 2026 by adding a supplier side duty, covered in our summary of the Utah disclosure law. Arizona now sits closer to Nevada, whose approach to unapproved biological therapies is permissive.
Frequently Asked Questions
What would Arizona SB 1214 have allowed if it passed?
SB 1214 would not have created a right to any therapy. It would have set conditions on providers already offering non-FDA-approved cell and tissue products, including continuing education, an all-caps disclosure, a five element consent, accredited or FDA-registered sourcing, and manufacturer validation records. The veto on June 19, 2026 means none of it applies.
Has SB 1214 been signed into law yet?
No. The bill passed the Senate on March 4, 2026, passed the House on June 9, 2026, and received final Senate passage on June 12, 2026. Governor Katie Hobbs vetoed it on June 19, 2026, and no override followed. It never took effect and never received an effective date.
What limitations did the bill include?
Scope covered cells, tissues, or biologic materials from adult donors or from afterbirth. Sourcing had to come from an FDA-registered or accredited facility. Serious adverse events would have gone to the regulatory board within 15 calendar days, and violations would have carried 10,000 dollars in statutory damages per violation plus attorney fees.
How would this affect adipose tissue banking in Arizona?
Banking was never the bill’s target, since it addressed providers administering products to patients. Adipose tissue from adult donors did fall inside the scope, so provider side documentation would have mattered more. After the veto, federal rules govern. Banking remains a preservation service that does not guarantee eligibility, access, or clinical benefit.
What governs stem cell activity in Arizona without this bill?
Federal law does. 21 CFR Part 1271 sets registration, donor eligibility, and current good tissue practice requirements, and 1271.10(a) decides whether a product is regulated solely as a tissue or as a drug and biologic needing approval. The FTC applies its Health Products Compliance Guidance to advertising claims.
Does Nevada require the disclosures Arizona considered?
No. Nevada has no stem cell disclosure law and no stem cell specific consent statute. Its 2009 provisions at NRS 629.300 to 629.390 are permissive and authorizing rather than restrictive, a frequent point of confusion. Arizona and Nevada now sit in the same category, with federal rules doing the work.
Key Takeaways
Arizona SB 1214 is not law. It passed both chambers in 2026 and was vetoed on June 19, 2026, so its requirements never took effect and its two proposed statute sections were never added. The bill would have gone further than most enacted laws by combining continuing education, an all-caps disclosure, a five element consent, accredited sourcing, adverse event reporting, and a private right of action.
None of that binds anyone in Arizona today. Providers there work under the federal framework, which means 21 CFR Part 1271 for tissue products and FTC guidance for advertising. Federal enforcement continues regardless of the veto. For patients, the point is unchanged. Adipose tissue and stromal vascular fraction remain investigational, banking preserves tissue rather than providing therapy, and individual outcomes cannot be predicted.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Patients weighing adipose tissue banking can review current options and pricing, and anyone with questions about the process can contact our team.
Save My Fat partners with a U.S.-based tissue bank for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about banking, treatment, or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: state stem cell laws.
